Intervacc AB is a startup based in Sweden.
Intervacc AB is a Swedish biotechnology company that develops recombinant protein fusion–based vaccines for animal health, including Strangvac® for equine strangles. The group includes subsidiaries Nordvacc Läkemedel and Mybac-Vettech and operates a sales organization active on the European animal health market.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.